Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Change in Accured Expenses data on file, last reported at -$7.2 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$7.2 million, up 38.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.9 million (up 50.53% YoY), and the FY2025 annual result was $7.4 million, up 76.72% from the prior year.
• Change in Accured Expenses eased to -$7.2 million in Q1 2026 per KYMR's latest filing, from $13.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $13.7 million in Q4 2025 and troughed at -$15.4 million in Q1 2024.
• A 5-year average of $709235.3 and a median of $2.7 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 1069.36% in 2022, then soared 578.32% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $2.8 million in 2022, then surged by 139.02% to $6.8 million in 2023, then jumped by 32.81% to $9.0 million in 2024, then jumped by 51.43% to $13.7 million in 2025, then plunged by 152.77% to -$7.2 million in 2026.
• Business Quant data shows KYMR's Change in Accured Expenses at -$7.2 million in Q1 2026, $13.7 million in Q4 2025, and $664000.0 in Q3 2025.